Viventia Files for IPO
Viventia Bio has filedwith the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Viventia Bio has filed an F-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were given in the filing, but the offering is valued up to $86.25 million. The company intends to list on the Nasdaq Global Market under the symbol VITA.
The underwriters for this offering are Leerink Partners, Cowen and Guggenheim Securities.
This biologics oncology company is focused on designing, engineering and developing targeted protein therapeutics (TPTs). Its most advanced product candidates, Vicinium and Proxinium, are locally administered TPTs. In the third quarter of 2015, Viventia commenced a Phase 3 clinical trial for the lead product candidate, Vicinium, for the treatment of high-grade non-muscle invasive bladder cancer in the United States and Canada.
The company intends to begin enrollment by the end of the first quarter of 2016 for a Phase 3 clinical trial of Proxinium for the treatment of late-stage squamous cell carcinoma of the head and neck in the United States. Similar to existing antibody-drug conjugates, its TPTs are comprised of a targeting moiety that specifically binds to cancer cells and delivers a cytotoxic payload. Viventia has designed its TPTs to overcome the fundamental efficacy and safety challenges inherent in existing ADCs. The company is also developing cancer therapies for systemic administration utilizing its TPT platform, and it may explore additional therapeutic indications for Vicinium and Proxinium.
As for the net proceeds from this offering, Viventia intends to use them for the further research and development of its pipeline. The remainder will be used to in-license, acquire or invest in complementary businesses, intellectual property, products or assets. However, it has no current commitments or obligations to do so.
ALSO READ: The Strongest Performing Biotech in 2015 Is a Surprise
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
